Vascular Biogenics - VBLT Stock Forecast, Price & News

Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Its programs are based on its vascular targeting system, a gene-based technology targeting newly formed blood vessels; and monocyte targeting technology, an antibody-based technology that enables specifically inhibit monocyte migration for immune-inflammatory applications. The company's lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the recurrent platinum-resistant ovarian cancer; and Phase II clinical trials treatment of recurrent glioblastoma and colorectal cancer, as well as has completed Phase II clinical trial for the treatment of thyroid cancer. It is also developing VB-601 for various inflammatory indications, and VB-611 for various solid tumors. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.

Vascular Biogenics Trading Up 6.6 %

VBLT Stock opened at $0.25 on Tuesday. The company's 50 day moving average is $1.26 and its 200 day moving average is $1.41. The stock has a market cap of $17.47 million, a price-to-earnings ratio of -0.55 and a beta of 0.58. Vascular Biogenics has a 1-year low of $0.21 and a 1-year high of $2.54.

Vascular Biogenics (NASDAQ:VBLT - Get Rating) last posted its quarterly earnings data on Tuesday, May 17th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The company had revenue of $0.11 million during the quarter, compared to the consensus estimate of $0.20 million. Vascular Biogenics had a negative return on equity of 69.21% and a negative net margin of 4,894.40%. During the same quarter last year, the company posted ($0.12) earnings per share. As a group, sell-side analysts forecast that Vascular Biogenics will post -0.51 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on VBLT shares. StockNews.com started coverage on shares of Vascular Biogenics in a report on Saturday. They issued a "sell" rating on the stock. Jonestrading reissued a "buy" rating and issued a $5.00 price target on shares of Vascular Biogenics in a report on Friday, May 20th. Chardan Capital downgraded shares of Vascular Biogenics from a "buy" rating to a "neutral" rating in a report on Wednesday, July 20th. HC Wainwright downgraded shares of Vascular Biogenics from a "buy" rating to a "neutral" rating in a report on Wednesday, July 20th. Finally, Oppenheimer downgraded shares of Vascular Biogenics from an "outperform" rating to a "market perform" rating in a report on Wednesday, July 20th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the stock. According to MarketBeat.com, Vascular Biogenics has a consensus rating of "Hold" and an average price target of $4.88.